T. Kakehi

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.

T. Kishimoto, K. Yoshizaki, N. Nishimoto, 2003, The Journal of rheumatology.

Castleman disease IL-6 receptor antibody , tocilizumab , in patients with rheumatoid − anti interleukin-6 ( IL-6 ) and soluble IL-6 receptor after administration of an Mechanisms and pathologic significances in increase in serum

N. Nishimoto, N. Takagi, T. Mima, 2008 .

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

N. Nishimoto, N. Takagi, T. Mima, 2008, Blood.